Opportunities for web-based drug repositioning: Searching for potential antihypertensive agents with hypotension adverse events

Journal of Medical Internet Research

Volumn 18, Issue 4, 2016, Pages

  Wang, Kejian ^a   Wan, Mei ^b   Wang, Rui Sheng ^c   Weng, Zuquan ^b  

^a CoMed Technology and Consulting Co Ltd ^*  (Hong Kong)

^b FUZHOU UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

Author keywords

Antihypertensive drugs; Big data; FAERS; Fda adverse event reporting system; Hypotension; OpenFDA; Web based drug repositioning

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADVERSE DRUG REACTION; CHEMICALLY INDUCED; DRUG REPOSITIONING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; HYPOTENSION; INTERNET; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIHYPERTENSIVE AGENTS; DRUG REPOSITIONING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPERTENSION; HYPOTENSION; INTERNET; PHARMACOVIGILANCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84973352442     PISSN: None     EISSN: 14388871     Source Type: Journal    
DOI: 10.2196/jmir.4541     Document Type: Article

References (48)

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov2004 Aug;3(8):673-683. [doi: 10.1038/nrd1468] [Medline: 15286734]
2. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009Mar;22(2):119-125. [doi: 10.1358/dnp.2009.22.2.1303818] [Medline: 19330170]
3. Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One 2010;5(3):e9568 [FREE Full text] [doi: 10.1371/journal.pone.0009568] [Medline: 20221449]
4. Luo H, Chen J, Shi L, Mikailov M, Zhu H, Wang K, et al. DRAR-CPI: A server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res 2011 Jul;39(Web Server issue):W492-W498 [FREE Full text] [doi: 10.1093/nar/gkr299] [Medline: 21558322]
5. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011 Jun 8;13(6):627-638 [FREE Full text] [doi: 10.1016/j.cmet.2011.03.020] [Medline: 21641545]
6. Wang K, Sun J, Zhou S, Wan C, Qin S, Li C, et al. Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity. PLoS Comput Biol 2013;9(11):e1003315 [FREE Full text] [doi: 10.1371/journal.pcbi.1003315] [Medline: 24244130]
7. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011 Aug 17;3(96):96ra77 [FREE Full text] [doi: 10.1126/scitranslmed.3001318] [Medline: 21849665]
8. Campillos M, Kuhn M, Gavin A, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008Jul 11;321(5886):263-266 [FREE Full text] [doi: 10.1126/science.1158140] [Medline: 18621671]
9. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 2011Jul;90(1):133-142 [FREE Full text] [doi: 10.1038/clpt.2011.83] [Medline: 21613990]
10. Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS One 2011;6(12):e28025 [FREE Full text] [doi: 10.1371/journal.pone.0028025] [Medline: 22205936]
11. Wang K, Weng Z, Sun L, Sun J, Zhou S, He L. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases. Biochem Biophys Res Commun2015 Feb 13;457(3):249-255. [doi: 10.1016/j.bbrc.2014.12.096] [Medline: 25576362]
12. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365(9455):217-223. [doi: 10.1016/S0140-6736(05)17741-1] [Medline: 15652604]
13. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003 Jul 9;290(2):199-206. [doi: 10.1001/jama.290.2.199] [Medline: 12851274]
14. Feig PU, Roy S, Cody RJ. Antihypertensive drug development: current challenges and future opportunities. J Am Soc Hypertens 2010;4(4):163-173. [doi: 10.1016/j.jash.2010.04.003] [Medline: 20537610]
15. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: A systematic review. Health Policy 2011 Apr;100(1):4-17. [doi: 10.1016/j.healthpol.2010.12.002] [Medline: 21256615]
16. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ1991 Jul;10(2):107-142. [Medline: 10113009]
17. Young RC, Friedman MA, Schilsky RL, Sigal EV. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res 2007 May 1;13(9):2533-2534 [FREE Full text] [doi: 10.1158/1078-0432.CCR-07-0608] [Medline: 17473179]
18. Kuehn BM. FDA opens adverse event data. JAMA 2014 Jul 23;312(4):328. [doi: 10.1001/jama.2014.9120]
19. Hampton T. Data mining approach shows promise in detecting unexpected drug interactions. JAMA 2011 Jul 13;306(2):144. [doi: 10.1001/jama.2011.918] [Medline: 21750287]
20. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 2013;10(7):796-803 [FREE Full text] [doi: 10.7150/ijms.6048] [Medline: 23794943]
21. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011 Jun;34(6):1369-1371 [FREE Full text] [doi: 10.2337/dc10-2412] [Medline: 21515844]
22. Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 2012;9(5):322-326 [FREE Full text] [doi: 10.7150/ijms.4397] [Medline: 22745572]
23. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004 Aug;13(8):519-523. [doi: 10.1002/pds.1001] [Medline: 15317031]
24. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014 Jan;42(Database issue):D1091-D1097 [FREE Full text] [doi: 10.1093/nar/gkt1068] [Medline: 24203711]
25. Jarvelin K, Kekalainen J. Cumulated gain-based evaluation of IR techniques. ACM Trans Inf Syst 2002;20(4):422-446.
26. Zhang W, Ji L, Chen Y, Tang K, Wang H, Zhu R, et al. When drug discovery meets web search: Learning to Rank for ligand-based virtual screening. J Cheminform 2015;7:5 [FREE Full text] [doi: 10.1186/s13321-015-0052-z] [Medline: 25705262]
27. Ye H, Liu Q, Wei J. Construction of drug network based on side effects and its application for drug repositioning. PLoS One 2014;9(2):e87864 [FREE Full text] [doi: 10.1371/journal.pone.0087864] [Medline: 24505324]
28. Claveau V, Hamon T, Le MS, Grabar N. Health consumer-oriented information retrieval. Stud Health Technol Inform 2015;210:80-84. [Medline: 25991106]
29. Ullah MZ, Aono M, Seddiqui MH. Estimating a ranked list of human genetic diseases by associating phenotype-gene with gene-disease bipartite graphs. ACM Trans Intell Syst Technol 2015;6(4):1-21.
30. Hermida RC, Ayala DE, Calvo C, López JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005 Sep 20;46(6):975-983 [FREE Full text] [doi: 10.1016/j.jacc.2004.08.071] [Medline: 16168278]
31. Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Rodríguez M, et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension 2005 Oct;46(4):1060-1068 [FREE Full text] [doi: 10.1161/01.HYP.0000172623.36098.4e] [Medline: 16087788]
32. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens 2005 Sep;19(9):667-673. [doi: 10.1038/sj.jhh.1001910] [Medline: 16034448]
33. Grossmann M, Jamieson MJ, Kirch W. Effects of digoxin and digitoxin on circadian blood pressure profile in healthy volunteers. Eur J Clin Invest 1998 Sep;28(9):701-706. [Medline: 9767368]
34. Kirch C, Grossmann M, Fischer S, Neumeister V, Kirch W. Effect of digoxin on circadian blood pressure values in patients with congestive heart failure. Eur J Clin Invest 2000 Apr;30(4):285-289. [Medline: 10759875]
35. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997 May 28;277(20):1624-1632. [Medline: 9168293]
36. Haddy FJ, Vanhoutte PM, Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol 2006 Mar;290(3):R546-R552 [FREE Full text] [doi: 10.1152/ajpregu.00491.2005] [Medline: 16467502]
37. Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep 2011 Aug;13(4):309-317. [doi: 10.1007/s11906-011-0197-8] [Medline: 21403995]
38. Qian Y, Ye X, Du W, Ren J, Sun Y, Wang H, et al. A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems. Br J Clin Pharmacol 2010 Jan;69(1):67-73 [FREE Full text] [doi: 10.1111/j.1365-2125.2009.03557.x] [Medline: 20078614]
39. Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM 2007 Nov;100(11):691-697 [FREE Full text] [doi: 10.1093/qjmed/hcm088] [Medline: 17932098]
40. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J May;33(9):1058-1066 [FREE Full text] [doi: 10.1093/eurheartj/ehs041] [Medline: 22507981]
41. Powell J, Buchan I. Electronic health records should support clinical research. J Med Internet Res 2005;7(1):e4 [FREE Full text] [doi: 10.2196/jmir.7.1.e4] [Medline: 15829476]
42. Xie B, Wang M, Feldman R, Zhou L. Internet use frequency and patient-centered care: measuring patient preferences for participation using the health information wants questionnaire. J Med Internet Res 2013;15(7):e132 [FREE Full text] [doi: 10.2196/jmir.2615] [Medline: 23816979]
43. Buchan NS, Rajpal DK, Webster Y, Alatorre C, Gudivada RC, Zheng C, et al. The role of translational bioinformatics in drug discovery. Drug Discov Today 2011 May;16(9-10):426-434. [doi: 10.1016/j.drudis.2011.03.002] [Medline: 21402166]
44. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343 [FREE Full text] [doi: 10.1038/msb.2009.98] [Medline: 20087340]
45. Bisgin H, Liu Z, Kelly R, Fang H, Xu X, Tong W. Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics 2012;13 Suppl 15:S6 [FREE Full text] [doi: 10.1186/1471-2105-13-S15-S6] [Medline: 23046522]
46. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 2003 Jan;18(1):57-60 [FREE Full text] [Medline: 12534765]
47. Gerber BS, Eiser AR. The patient physician relationship in the Internet age: future prospects and the research agenda. J Med Internet Res 2001;3(2):E15 [FREE Full text] [doi: 10.2196/jmir.3.2.e15] [Medline: 11720957]
48. Hart A, Henwood F, Wyatt S. The role of the Internet in patient-practitioner relationships: findings from a qualitative research study. J Med Internet Res 2004 Sep 30;6(3):e36 [FREE Full text] [doi: 10.2196/jmir.6.3.e36] [Medline: 15471762]